Adma Biologics (ADMA) Other Accumulated Expenses (2016 - 2025)

Adma Biologics has reported Other Accumulated Expenses for 8 years, with the latest figure at $4.2 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses rose 108.82% year-over-year to $4.2 million; the trailing twelve-month figure through Dec 2025 stood at $4.2 million (up 108.82% YoY), and the FY2025 full-year result was $4.2 million, up 108.82% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $4.2 million, up from $2.6 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $17.5 million in Q2 2025, with the low at $981721.0 in Q4 2021.
• Historically, Other Accumulated Expenses has averaged $3.1 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 33.89% — and 2025, when it jumped 663.13%.
• Adma Biologics' Other Accumulated Expenses stood at $981721.0 in 2021, then soared by 82.94% to $1.8 million in 2022, then jumped by 31.68% to $2.4 million in 2023, then retreated by 15.6% to $2.0 million in 2024, then surged by 108.82% to $4.2 million in 2025.
• The last three Other Accumulated Expenses figures came in at $4.2 million (Q4 2025), $2.6 million (Q3 2025), and $17.5 million (Q2 2025), per Business Quant data.